Buy & Sell TG Therapeutics Inc (TGTX) – TG Therapeutics Inc Price Today
Aura AI Summary
Key Stats
- $7.70BMarket Cap
- HealthSector
- -15.07%3M Drawdown
- $7.94BEnterprise Value
- -Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 6 daysTypical Hold Time
TG Therapeutics Inc (TGTX) is currently valued at a market capitalization of $7.70B, with an enterprise value of $7.94B. Over the past 52 weeks, TG Therapeutics Inc has traded between a low of $26.39 and a high of $50.49, highlighting its annual price range. Over the past three months, TG Therapeutics Inc has recorded a drawdown of -15.07%, reflecting recent price volatility. On average, investors hold TG Therapeutics Inc for approximately 6 days, indicating typical investor behavior on the platform.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Most Recent News
Defiance ETFs launches SPCQ, a 2x inverse leveraged ETF targeting daily SpaceX stock declines.
Defiance ETFs introduced the Defiance Daily Target 2X Short SpaceX ETF (SPCQ), designed to provide investors with double inverse exposure to SpaceX's daily stock price movements. This ETF aims to deliver -200% of SpaceX's daily returns, allowing inve...

Halper Sadeh LLC probes fairness of recent major company sales and mergers for shareholders.
Halper Sadeh LLC, an investor rights law firm, is investigating whether shareholders of Open Lending Corporation, Nuvalent, Organon & Co., and SUNation Energy are receiving fair deals in their companies' recent sales or mergers. The firm suggests ins...

Global GLP-1 receptor agonist market to reach $95.3B by 2035, growing at 12.1% CAGR driven by diabetes and obesity demand.
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
